MNX Market Network Exchange
Commercial intelligence · New York
Menu
MarketAwardsContracts and grants already awardedOpportunitiesRFPs and grants open nowPolicyBills, laws, and regulationsProgramsNamed funding initiatives and who they fundCalendarUpcoming committee hearings and meetings
NetworkOfficialsEveryone holding public office in New York City and StateOrganizationsPublic and civic sector organizations across New YorkLobbyingWho is registered to lobby, for which client, and for how much
ExchangeMarket structureWho funds a sector, how concentrated it is, and who is establishedStakeholder mapThe offices whose remit intersects your work, mapped to your siteLobbying landscapeWho is already lobbying your space, the most-lobbied offices, and what representation costsDossiersOne reconciled file on any organization, agency, or officialMonitorAlerts on new money, RFPs, and mentions you trackBuild a PlanA strategic plan customized for you
AboutHire a consultant ↗
Sign inGet Pro
Build my strategy
$1,000The New York strategy we build for retained clients, made accessible.Build my strategy →

New York policy

S6758: Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

NY Senate · Sponsor Nathalia Fernandez

Watch this bill · sign in
ShareLinkedIn ↗Email
Jurisdiction
New York State
Applies to
New York State (proposed)
Effective
May 29, 2026

What it requires

Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

ny-statesenatelegislationbill

Official source ↗

Free account

Create a free account

Track New York policy and save searches across the Network. Free. No card required.

Continue with GoogleContinue with LinkedIn
or email

Want to turn policy like this into market and network moves? Build your Market Network Strategic Plan →